title: Pinitol supplementation does not affect insulin-mediated glucose metabolism and muscle insulin receptor content and phosphorylation in older humans.
abstract: This study assessed the effect of oral pinitol supplementation on oral and intravenous glucose tolerances and on skeletal muscle insulin receptor content and phosphorylation in older people. Fifteen people (6 men, 9 women; age 66 +/- 8 y; BMI 27.9 +/- 3.3 kg/m(2); hemoglobin A1c 5.39 +/- 0.46%, mean +/- SD) completed a 7-wk protocol. Subjects were randomly assigned to groups that during wk 2-7 consumed twice daily either a non-nutritive beverage (Placebo group, n = 8) or the same beverage with 1000 mg pinitol dissolved into it (Pinitol group, n = 7, total dose = 2000 mg pinitol/d). Testing was done at wk 1 and wk 7. In the Pinitol group with supplementation, 24-h urinary pinitol excretion increased 17-fold. The fasting concentrations of glucose, insulin, and C-peptide, and the 180-min area under the curve for these compounds, in response to oral (75 g) and intravenous (300 mg/kg) glucose tolerance challenges, were unchanged from wk 1 to wk 7 and were not influenced by pinitol. Also, pinitol did not affect indices of hepatic and whole-body insulin sensitivity from the oral glucose tolerance test and indices of insulin sensitivity, acute insulin response to glucose, and glucose effectiveness from the intravenous glucose tolerance test, estimated using minimal modeling. Pinitol did not differentially affect total insulin receptor content and insulin receptor phosphotyrosine 1158 and insulin receptor phosphotyrosine 1162/1163 activation in vastus lateralis samples taken during an oral-glucose-induced hyperglycemic and hyperinsulinemic state. These data suggest that pinitol supplementation does not influence whole-body insulin-mediated glucose metabolism and muscle insulin receptor content and phosphorylation in nondiabetic, older people.
authors.affiliation: Department of Foods and Nutrition, Purdue University, West Lafayette, IN, USA. campbellw@purdue.edu
authors.forename: Wayne W
authors.initials: WW
authors.lastname: Campbell
authors.forename: Mark D
authors.initials: MD
authors.lastname: Haub
authors.forename: James D
authors.initials: JD
authors.lastname: Fluckey
authors.forename: Richard E
authors.initials: RE
authors.lastname: Ostlund
authors.forename: John P
authors.initials: JP
authors.lastname: Thyfault
authors.forename: Hannah
authors.initials: H
authors.lastname: Morse-Carrithers
authors.forename: Matthew W
authors.initials: MW
authors.lastname: Hulver
authors.forename: Zonda K
authors.initials: ZK
authors.lastname: Birge
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood; D019587:Dietary Supplements; D005215:Fasting; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007294:Inositol / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood / Q000652:urine; D007328:Insulin / Q000097:blood / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000737:chemistry*; D010766:Phosphorylation; D019000:Phosphotyrosine / Q000032:analysis; D010919:Placebos; D011972:Receptor, Insulin / Q000032:analysis* / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D010919:Placebos; D019000:Phosphotyrosine; C021730:pinitol; D007294:Inositol; D011972:Receptor, Insulin